Greenwich Lifesciences Inc
GLSI
NASDAQ
Biotechnology
$16.80
USD
+0.42 (+2.56%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $240.28M
Volume 116.5K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-21.68M
TTM
-15.2%
YoY
Operating Cash Flow
$-12.49M
TTM
-46.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 0.4 | 0.7 | 0.4 | 0.5 | 0.5 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 3.8 | 4.2 | 7.9 | 5.7 | 4.0 |
Operating Income | -3.8 | -4.2 | -7.9 | -5.7 | -4.0 |
EBITDA | -3.8 | -4.2 | -7.9 | -5.7 | -4.0 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 |
Income Before Income Taxes | -3.7 | -4.2 | -7.9 | -5.7 | -3.9 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -3.7 | -4.2 | -7.9 | -5.7 | -3.9 |
Consolidated Net Income / Loss | -3.7 | -4.2 | -7.9 | -5.7 | -3.9 |
Net Income Attributable to Common Shareholders | -3.7 | -4.2 | -7.9 | -5.7 | -3.9 |
Basic EPS | -$0.28 | -$0.30 | -$0.57 | -$0.39 | -$0.27 |
Diluted EPS | -$0.28 | -$0.30 | -$0.57 | -$0.39 | -$0.27 |
Basic Shares Outstanding | 13.4M | 13.6M | 14.0M | 14.6M | 14.6M |
Diluted Shares Outstanding | 13.4M | 13.6M | 14.0M | 14.6M | 14.6M |